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Abstract: Sleep disturbance has been found to trigger a stress response with a subsequent 
activation of the psychoneuroimmunological (PNI) pathway associated with adverse health 
outcomes. This study aimed to assess the association among selected PNI biomarkers, 
sleep disturbances, and adverse health outcomes (depressive symptoms, physical symptoms). 
A stratified, quota sample (14 poor sleepers and 15 good sleepers) was drawn from a pool 
of healthy college women from a larger scale of study. The participants reported their 
sleep, stress, depressive, and physical symptoms. Wrist actigraphy was used to collect 
objective sleep data, and the Enzyme-Linked ImmunoSorbent Assay was used to assess 
PNI biomarkers. Poor sleep quality, higher stress perception, elevated serum serotonin, and 
lower serum interleukin-10 explained 75.3% of the variances for the depressive symptoms. 
Poor sleep quality along with delayed peak activity rhythms accounted 31.4% of the 
physical symptoms. High serotonin and tumor necrosis factor-α were the significant 
predictors for poor sleep efficiency, and serotonin was the single significant predictor for 
poor daytime functioning. Stress and sleep disturbances negatively impact the health of 
college women and should be as part of regular check-ups on campus. PNI effects on 
health outcomes should be further explored. Educational materials in the areas of sleep 
hygiene, health impacts from sleep disturbances, and strategies to maintain synchronized 
circadian rhythms should be mandatorily included in the college curriculum. 
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1. Introduction 
Sleep disturbances are more prevalent among American females than males, according to the 2007 
Sleep in America Poll survey that found about half of the women in the United States experienced 
sleep problems nightly [1]. Sleep disturbances have been found to trigger a stress response with 
subsequent activation of the psychoneuroimmunological (PNI) pathway that has an impact on fatigue, 
depression, and adverse health outcomes [2,3]. The pro-inflammatory cytokines, such as interleukin 
(IL)-1, IL-6, and tumor necrosis factor (TNF)-α, increase slow wave sleep; and the anti-inflammatory 
cytokines, such as IL-4 and IL-10, inhibit sleep [4]. Thus, studies of the association between sleep and 
health outcomes should also consider PNI markers as the predictor. 
Sleep disturbances are prevalent in the U.S.; however, many Americans do not take actions that 
address their sleep problems [5]. It has been found that about 45% of adolescents do not sleep enough [6]; 
studies of college students have found that more than 60% of them were poor sleepers [7,8]. Compared 
to men, women are more vulnerable to the effects of sleep disturbances because of cycling hormones 
and engagement in multiple social roles [1,9]. Although there is emerging evidence of the relationships 
between sleep disturbances and adverse health outcomes [10], most of the findings have been derived 
from studies with a specific disease-based population or with healthy human beings but under an 
artificial context, such as monitoring sleep in the sleep lab. A study in a natural context and over an 
extended period of time may lead to a better understanding of the pathway between sleep disturbances 
and health outcomes. 
Little is known about the associations among PNI biomarkers, sleep disturbances, and adverse 
health outcomes in healthy adult women. Without prospective data, gaps remain in our understanding 
of the mechanisms underlying how sleep disturbances earlier in life may contribute to future health 
problems. Better understanding of these mechanisms may lead to tailored interventions to prevent or 
delay health problems. In this prospective, stratified quota, comparative study, we intend to lay the 
foundation for a developmental model of the role of sleep in several key mechanisms responsible for 
adverse health-related wellbeing (depressive symptoms, physical symptoms) and PNI markers in 
female adults. 
The biomarkers selected for this study are based on PNI effects resulting from sleep disturbances as 
reported in prior studies [3,11], and include: (1) Endocrine axis: cortisol, melatonin, serotonin;  
(2) Immune axis: pro-inflammatory, such as IL-1β, IL-6, TNF-α, anti-inflammatory cytokines (i.e.,  
IL-10), and C-reactive protein (CRP). For example, cortisol is usually referred to as the “stress 
hormone” as it is involved in the response to stress—it increases blood pressure and blood sugar, and 
disturbs sleep [12]. CRP responds to pro-inflammatory cytokines, particularly IL-6 and is considered a 
sensitive marker of low-grade inflammation [13]. Studies have demonstrated an inverse correlation 
between CRP concentration and cardiovascular disease in both type 1 and type 2 diabetes [14]. The 
specific aim of this study was to assess the associations among selected PNI biomarkers, sleep 
disturbances, and adverse health outcomes (morning fatigue, depressive symptoms, and physical 
symptoms). The following research questions were addressed:  
1. Are there any differences in the characteristics of perceived stress, morning fatigue severity, 
depressive symptoms, daytime sleepiness, nocturnal total sleep time, activity level, physical 
symptoms, and PNI markers between the good sleepers and poor sleepers? 
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2. To what degree are depressive symptoms explained by the individual’s personal characteristics 
(i.e., age, body mass index), perceived stress, sleep disturbances, and PNI markers? 
3. To what degree are physical symptoms explained by an individual’s personal characteristics 
(i.e., age, body mass index), perceived stress, sleep disturbances, and PNI markers? 
2. Methods 
2.1. Study Design and Participants 
The Impaired Sleep Model [15] was used to guide this correlational exploratory study. Approval for 
this study was obtained from the University Institutional Review Board in the southern United States. 
Informed consent was obtained from each study participant. The participants (15 poor sleepers and  
14 good sleepers) in the current 3-day study were a cohort from a larger scale study, which was a  
7-day, prospective, naturalistic observation study [8]. Details of the larger scale study has been 
reported elsewhere [8]; in brief, the study participants were college women at least 18 years of age and 
self-reported without any existing physical and mental disorders. Sleep strata (see Table 1), determined 
by the Pittsburg Sleep Quality Index (PSQI) [16] and Sleep Deviation Index (SDI) [17], was used to 
classify poor or good sleepers. The SDI is an absolute value of the ratio of the difference between 
actual total sleep time and preferred sleep time to 24 hours. The poor sleeper was operationally defined 
as occurring when an individual scored more than five on the PSQI and in the highest quintile in the 
SDI in both school and non-school nights. The SDI ranges from 0 to 1; a deviation index of 0 reflects a 
perfect match between the amount of sleep that is needed and the amount of sleep actually acquired [17]. 
Table 1. Selection strata. 
Sleep stratum 
Phase I sleep quality 
index in the PSQI 
Phase I school night 
sleep deviation index 
Phase I non-school night 
sleep deviation index 
Poor sleeper >5 Highest quintile Highest quintile 
Good sleeper ≤5 Lowest quintile Lowest quintile 
2.2. Study Instruments 
The following instruments were used for data collection in the current study. A structured 
demographic form was used for collecting demographic information. Sleep disturbances in the week 
immediately preceding the questionnaire were assessed by the General Sleep Disturbance Scale 
(GSDS), a 21-item, 0–7 rating scale; a score equal or above 3 indicates poor sleepers [18]. Sleep 
disturbances in the past month were evaluated by the Pittsburgh Sleep Quality Index (PSQI), a 19-item, 
0–3 rating scale; a score above 5 suggests insomnia [16]. The PSQI includes 7-subscale: sleep quality, 
sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleeping medication, and 
daytime dysfunction. Daytime sleepiness was measured by the Epworth Sleepiness Scale (ESS),  
an 8-item, 0–3 rating questionnaire; higher scores indicate a higher degree of sleepiness [19]. 
The Numerical Rating Scale for Fatigue (NRS-F) [20], a 7-item scale with a possible score range of 
0–10 (highest severity), was used to assess morning fatigue. The NRS-F has been used in several 
studies with healthy adult women. The Center for Epidemiologic Studies Depression Scale (CESD) [21], 
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a 20-item scale with a possible score range of 0–60, was used to measure the study participants’ 
depressive symptoms. Study participants with CESD scores ≥16 were referred to their healthcare 
provider for further assessment. The Physical Symptom Inventory (PSI) [22], an 18-item scale with 
two subscales (symptoms (e.g., headache, infection) and symptoms-related doctor visit) was used to 
measure participants’ physical health. The possible score range is 0–18 for each subscale. The 
perceived stress measured by the Perceived Stress Scale (PSS) [23], a 10-item scale with a possible 
score range of 0 to 40, was used to assess the stress level results from daily life. All of these 
instruments have established reliability and validity, and have been used in our previous studies, with 
the exception of the PSI; however, it has been used in several studies with college students. 
In addition to the self-reported questionnaires, we also included objective measurements in this 
study: wrist actigraph and PNI biomarkers. A wrist actigraph is a light-weight, watch-like motion 
sensor monitor (Mini Motionlogger Actigraphy, octagonal motionlogger, Ambulatory Monitoring Inc., 
Ardsley, NY, USA), which was used to measure total nocturnal and daytime sleep time, wake after 
sleep onset, and circadian activity rhythms. The assays kits (described later), which have excellent 
measurement properties, were used for evaluating the selected PNI-affected biomarkers by using  
a 7 mL blood sample. 
2.3. Procedure 
The questionnaires, along with wrist actigraphy data, and selected PNI biomarkers, were collected. 
Blood sample collection appointments at the Biology Department were coordinated by the first author 
to a written protocol and corresponded to the participants’ menstruation cycle (within 7 days after the 
menstruation period). In order to ensure valid measurements, the samples were obtained under the 
following standard conditions: (1) the participant sat in a comfortable position; (2) blood was drawn by 
a skillful phlebotomist by venipuncture through a 21-gauge needle with one attempt, the phlebotomist 
waited for at least 20 minutes prior to the second attempt if the first attempt was not successful; (3) the 
room was comfortably warm and quiet; (4) all fasting blood draws were done in the morning between 
7:30 and 9:00 a.m.; and (5) a light breakfast, including milk or soy milk and nutrient bar, were 
provided after the blood draw. All study participants were asked to sit in the lab for a few minutes to 
ensure no adverse event (e.g., dizziness, uncomfortable feelings) occurred before they left the lab. 
At the end of the 3-day study, all the participants received a sleep hygiene booklet [24], a report on 
her sleep patterns, and a report of any abnormal biomarkers for her to discuss with her primary health 
care provider. All the blood samples were labeled with an assigned code number and stored in a 
freezer (−80 °C) until assay. Only the first author had access to the code book. 
2.4. Data Analysis 
The data were generated in the following categories for each subject: (1) demographic data;  
(2) self-reported stress, sleep data, and morning fatigue; (3) two indices of adverse health outcomes 
(CESD, PSI); (4) selected PNI biomarkers; and (5) wrist actigraphy data. The wrist actigraphy data 
were analyzed using activity counts to determine sleep maintenance using Webster’s criteria [25]. The 
automatic sleep-scoring program (Action 4, software program, Ambulatory Monitoring Inc., Arbsley, 
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NY, USA) was used to calculate TST (total sleep time) in minutes and WASO (wake after sleep onset) 
in percentage. The average of the 3-day TST and WASO were used for data analysis. 
The biomarker analyses were performed in the lab at the Biology Department in the University 
using established laboratory protocols for specimen handling and analysis. Preparations of assay 
controls followed the instructions from the manufacturers. Inflammatory cytokines (IL-6, TNF-α,  
IL-1b, and IL-10), CRP, melatonin, serotonin, and cortisol were measured using the Enzyme-Linked 
ImmunoSorbent Assay (ELISA). Cytokines were measured sing “sandwich” ELISA kits purchased 
from BD Biosciences (San Jose, CA, USA). CRP levels in the serum were detected by using “sandwich” 
ELISA purchased from LDN, Germany. Serotonin and cortisol levels in the serum were detected using 
“competition” ELISA kits purchased from LDN, Germany. Melatonin levels in the serum were 
quantified using “competition” ELISA kits purchased from GenWay Biotech, Inc. (San Diego, CA, 
USA). A standard curve was plotted using the absorbance readings measured for standards against the 
known concentration of the standards. Non-linear regression, recommended by the manufacturers, was 
used to interpolate the protein concentration in the samples from the standard curve. 
We entered data into Statistical Package for the Social Sciences (SPSS), version 18.0. Internal 
consistency reliability of the survey instruments was calculated as appropriate using Cronbach’s alpha 
coefficients. Descriptive statistics were used to describe the sample characteristics, PNI biomarkers, 
sleep variables, and adverse health outcomes. Chi-Square tests and ANOVAs were used to examine 
possible differences on demographic variables between the two groups (poor and good sleepers). 
Correlations, regression models, and t-tests were used to answer the research questions.  
3. Results 
Based on the PSQI score and the SDI from the larger scale study, a total of 29 students with a mean 
age of 25.3 (SD = 7.1) who met the inclusion criteria as either good sleepers (n = 14) or poor sleepers 
(n = 15) were invited back for the current study (see Table 2). Independent t-tests showed there  
were statistically significant differences between good and poor sleepers on the PSQI global score  
(t [27] = −5.08, p < 0.001) and SDI in both full week (t [27] = −2.37, p < 0.05) and weekdays  
(t [27] = −3.14, p = 0.004). 
3.1. Characteristics between Good Sleepers and Poor Sleepers 
Table 3 presents descriptive statistics for perceived stress, daytime sleepiness, depressive symptoms, 
physical symptoms, nocturnal total sleep time, wake after sleep onset, circadian activity rhythms, 
morning fatigue severity, acrophase (peak activity level), and biomarker variables for the whole group 
in the current study and for the two subgroups (good and poor sleepers). Compared to the good 
sleepers the poor sleepers reported statistically significantly higher stress perception, depressive 
symptoms, daytime sleepiness, and more adverse physical symptoms. Compared to the good sleepers, 
the poor sleepers had higher levels of pro-inflammatory cytokines (IL1-β, IL-6, and TNF-α),  
anti-inflammatory cytokines (IL-10), cortisol, and serotonin levels; however, there were no statistically 
significant differences between the two groups in this small sample. On the other hand, compared to 
the good sleepers, CRP and melatonin levels were lower in the poor sleepers, though there were no 
statistically significant differences. 
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Table 2. Characteristics of the study participants. 
Variables 
Whole Group 
(N = 29) 
Good Sleepers 
(n = 14) 
Poor Sleepers 
(n = 15) 
Age, years (Mean ± SD) 25.3 ± 7.1 24.9 ± 4.8 25.8 ± 8.9 
Ethnic group (n[%])    
White 8 (27.6) 4 (28.6) 4 (26.7) 
Black 9 (31.0) 3 (21.4) 6 (40.0) 
Hispanic 4 (13.8) 4 (28.6) --- 
Asian 8 (27.6) 3 (21.4) 5 (33.3) 
Currently working (n[%]) 15 (51.7) 9 (64.3) 6 (40.0) 
Marital status (n[%])    
Married/partner 9 (31.0) 5 (35.7) 4 (26.6) 
Single 19 (65.5) 9 (64.3) 10 (66.7) 
Financial difficulty (n[%]) 20 (69.0) 9 (64.3) 11 (73.3) 
BMI (Mean ± SD) 24.4 (6.6) 25.4 (7.8) 23.4 (3.5) 
SDI (Mean ± SE)    
7-days 0.054 ± 0.010 0.031 ± 0.007 0.075 ± 0.017 * 
Weekdays 0.066 ± 0.011 0.034 ± 0.008 0.095 ± 0.017 ** 
Weekends 0.051 ± 0.009 0.034 ± 0.009 0.067 ± 0.015 
PSQI (Mean ± SD) 6.27 ± 2.99 4.14 ± 4.1 8.3 ± 2.6 ** 
Note: * p < 0.05, ** p < 0.01. Abbreviations: BMI, Body Mass Index; SDI, Sleep Deviation Index;  
PSQI, Pittsburg Sleep Quality Index. 
Table 3. Mean and standard deviation (mean ± SD) for the major variables. 
Variables (cut-off) Whole Group (N = 29) Good Sleepers (n = 14) Poor Sleepers (n = 15) 
PSS (>13.6) 14.5 ± 6.5 11.4 ± 5.4 * 17.3 ± 6.3 * 
ESS (>9) 8.3 ± 4.8 5.5 ± 3.7 ** 11.0 ± 4.2 ** 
CESD (>16) 9.9 ± 7.3 6.5 ± 3.2 * 13.1 ± 8.7 * 
PSI 5.1 ± 2.9 3.9 ± 2.3 * 6.3 ± 2.9 * 
TST (<420 minutes) 397.8 ± 58.2 402.3 ± 41.8 393.6 ± 71.5 
WASO (>10%) 5.5 ± 4.1 4.9 ± 3.6 6.0 ± 4.6 
CAR 0.68 ± 0.11 0.70 ± 0.09 0.66 ±0.13 
NRS-F (>3.2) 3.6 ± 1.5 3.4 ± 1.4 3.7 ± 1.5 
Acrophase (time format) 15:43 ± 1:34 15:18 ± 1:16 16:09 ± 1:46 
IL-1B (pg/mL) 0.57 ± 0.65 0.34 ± 0.34 0.72 ± 0.84 
IL-6 (pg/mL) 4.16 ± 7.47 3.89 ±5.56 4.40 ± 9.1 
IL-10 (pg/mL) 15.99 ± 20.10 10.05 ± 5.57 21.53 ± 26.67 
TNF (pg/mL) 0.79 ± 1.50 0.49 ± 0.89 1.06 ± 1.89 
CRP (<6 mg/L) 2.88 ± 3.21 3.59 ± 3.98 2.23 ± 2.23 
Cortisol (µg/mL) 41.44 ± 3.04 40.90 ± 3.39 41.95 ± 2.70 
Melatonin (pg/mL) 37.62 ± 25.75 43.15 ± 32.61 32.47 ± 16.74 
Serotonin (ng/mL) 231.47 ± 321.05 162.82 ± 36.13 295.53 ± 442.52 
Note: * p < 0.05, ** p < 0.01. Abbreviations: PSS, Perceived Stress Scale; ESS, Epworth Sleepiness Scale; 
CESD, Central Epidemiologic Scale-Depression; PSI, Physical Symptom Inventory; TST, total sleep time; 
WASO, wake after sleep onset; CAR, Circadian Activity Rhythms; NRS-F, Numerical Rating Scale for 
Fatigue; IL, interleukin; TNF, Tumor Necrosis Factor; CRP, C-reactive protein. 
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Table 4 presents the non-parametric correlational analyses between biomarkers and stress (PSS), 
sleep disturbances (PSQI), daytime sleepiness (ESS), depressive symptoms (CESD), and total physical 
symptoms (PSI). Only two markers, serotonin and IL-10, had a statistically significant associated with 
the stress perception and sleep-associated variables in the small sample. Serotonin was significantly 
associated with poor sleep quality and more physical symptoms. IL-10 was the only marker 
significantly associated with severity of daytime sleepiness. Participants’ perception of their overall 
sleep quality during the past month was associated with lower stress levels, less daytime sleepiness, 
and fewer depressive and physical symptoms (p < 0.05). Those who reported more physical symptoms 
also experienced more daytime sleepiness (p < 0.05). 
Table 4. Correlations between stress, sleep, health-related well-being, and biomarkers (n = 29). 
Variables PSS PSQI ESS CESD PSI IL1-β IL-6 IL-10 TNF-α Cortisol CRP Melatonin Serotonin 
PSS ---             
PSQI 0.44 * ---            
ESS 0.58 ** 0.51 ** ---           
CESD 0.71 ** 0.57 ** 0.35 ---          
PSI 0.29 0.40 * 0.42 * 0.47 * ---         
IL-1β −0.01 0.05 0.04 −0.01 0.04 ---        
IL-6 −0.01 0.09 −0.03 0.02 −0.16 0.09 ---       
IL-10 0.28 0.17 0.42 * 0.02 0.09 0.17 0.32 ---      
TNF-α 0.26 0.16 0.004 0.18 −0.16 0.26 0.09 0.18 ---     
Cortisol −0.05 0.28 0.19 0.10 0.22 0.11 0.04 0.25 0.10 ---    
CRP −0.24 0.09 −0.29 −0.13 −0.18 −0.24 0.64 ** 0.10 −0.05 0.15 ---   
Melatonin 0.05 −0.07 0.09 0.13 −0.03 −0.13 0.06 0.12 0.11 0.31 −0.04 ---  
Serotonin 0.12 0.39 * 0.34 0.24 0.44 * −0.02 0.31 0.28 −0.26 0.41 * 0.30 0.25 --- 
Note: * p < 0.05, ** p < 0.01. Abbreviations: PSS, Perceived Stress Scale; PSQI, Pittsburg Sleep Quality Index; ESS, Epworth 
Sleepiness Scale; CES-D, Center of Epidemiology Scale-Depression; PSI, Physical Symptom Inventory; IL, interleukin; TNF, Tumor 
Necrosis Factor; CRP, C-reactive protein. 
3.2. Predictors for Depressive Symptoms and Physical Symptoms 
Regression models were used to explore which variables (personal characteristics, perceived stress, 
sleep disturbances, and PNI markers) were statistically associated with depressive symptoms and 
physical symptoms. The confounding variables, age and BMI, were entered first, and neither was a 
significant predictor for depressive symptoms and physical symptoms. Therefore, age and BMI 
variables were removed from the model and the stepwise regression was conducted for the stress, sleep 
disturbances and PNI markers variables. The PSQI global score (t = 3.66, p = 0.001) along with higher 
serotonin levels (t = 3.49, p = 0.002), perceived higher stress (t = 3.95, p = 0.001), and lower IL-10 
levels (t = −2.33, p = 0.029) explained 75.3% of the variances for the depressive symptoms which 
were measured by CESD (F [4, 23] = 21.61, p < 0.001). The global PSQI (t = 2.42, p = 0.023) along 
with acrophase (t = 2.27, p = 0.032) accounted for 31.4% of the physical symptoms (F [2, 25] = 7.18,  
p = 0.003), indicating the individuals with poor sleep quality and delayed peak activity rhythms  
(i.e., evening person) also experienced more physical symptoms. Because sleep disturbances measured 
by the global PSQI were the significant predictor for depressive symptoms and physical symptoms,  
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an exploratory analysis was conducted to examine if there is any association between the selected PNI 
biomarkers and PSQI, including both the global scale and its subscales. None of the biomarkers were 
the significant predictors for the global PSQI; however, serotonin (t = 3.94, p = 0.001) and TNF-α  
(t = 3.37, p = 0.002) are the significant predictors for poor sleep efficiency, and serotonin (t = 4.19,  
p < 0.001) was the single significant predictor for poor daytime functioning.  
4. Discussion 
This study examined to what degree depressive symptoms and physical symptoms were explained 
by the selected personal characteristics (i.e., age, body mass index), perceived stress, sleep 
disturbances, and PNI markers in a group of college women. In addition, we tested different 
characteristics of the PNI biomarkers between the good and poor sleepers. Data from this study 
showed college women are distressed, sleep deprived, sleepy during daytime, fatigued, and depressed. 
Poor sleep quality in the past month along with high serum serotonin levels, higher stress perception, 
and lower IL-10 predicted the severity of depressive symptoms. Poor sleep quality in the past month 
along with a delayed acrophase (peak activity level) predicted more physical symptoms. Data from this 
study showed that compared to the good sleepers the poor sleepers experienced significantly higher 
stress, more depressive symptoms, higher daytime sleepiness, and more adverse physical symptoms. 
Elevated pro-inflammatory cytokines, such as IL-6 and TNF-α, along with CRP have been found in 
depressive patients [26]; however, the association between CRP and depression is controversial. The 
third National Health and Nutrition Examination Survey (NAHANS III) database revealed that the 
association between depression and elevated levels of CRP was apparent in young male adults, and the 
comparable association was quite weak and not significant in women [27,28]. In the current study,  
we did not find an association between pro-inflammatory and depressive symptoms; instead, lower  
IL-10, an anti-inflammatory cytokine, along with higher serotonin were the predictors for depressive 
symptoms in these college women. This could be because none of the study participants were 
depressed patients; however, the finding is echoing the recent studies that increased IL-10 can reverse 
depressive symptoms [29,30]. Most of the literature documented an association between a low 
serotonin level and depressive symptoms; however, our study found that a high level of serotonin 
predicted depressive symptoms. This could be due to the fact that the majority of the study participants 
were sleep deprived. Serotonin catalyzes the second step in melatonin formation during night or dark, 
when an individual did not sleep well could cause serotonin accumulated because it could not convert 
to melatonin [31]. Although another study also found an association between high serotonin level and 
depression [32], this association needs to be further explored. In addition, the complex associations 
between depressive symptoms, neurotransmitters (e.g., norepinephrine and dopamine), and sleep 
should also be examined [33]. 
Prior studies also found that IL-6, TNF-α, and CRP are associated with cardiovascular diseases [34–37]. 
In this study, none of the biomarkers were a significant predictor for the total physical symptoms; 
however, poor sleep quality and delayed activity rhythms were the predictors for more physical 
symptoms. Physical activity has been associated with depression due to neurobiological effects from 
noradrenergic and serotonergic systems [38]. Circadian activity rhythms have been found to be related 
to symptom severity in dementia patients [39], seasonal affective disorder patients [40], and cancer 
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patients [41,42]. Circadian rhythms are generated by a central pacemaker, the suprachiasmatic nuclei 
(SCN), that is highly regulated and synchronized to elements of the external environment such as 
social activities and are closely linked to sleep, wakefulness, and health [43]. Findings from the current 
study warrant further study to explore the role of circadian activity rhythms in physical health among 
healthy women. 
An unexpected methodological finding in this study was the associations among PSQI, sleep 
deviation index (SDI), and circadian activity rhythms (CAR). The positive correlation between PSQI 
and SDI (r = 0.41, p = 0.017) indicates SDI could be a simple and valuable indicator for clinical sleep 
assessment. There was a negative correlation between SDI and CAR (r = −0.34), although it was not 
statistically significant in this small sample, which also indicates both SDI and CAR variables should 
be further explored in future studies. 
Although the findings from current study contribute to the knowledge in sleep disturbances and 
health outcomes among the general population; however, findings should be considered in light of the 
small sample size and a non-specific blood sample collection time point. The unexpected result of PNI 
biomarkers between the poor sleepers and good sleepers might be due to the small sample size of this 
study and the participants being healthy adults; thus, a larger scale study is needed to further validate 
the association between sleep disturbances and PNI biomarkers. In addition, the production of the 
selected biomarkers is related to circadian rhythms; however, we did not collect the blood sample in a 
specific time point. Therefore, a specific time point should be used to collect blood sample to increase 
the validity of the findings. However, an alternative explanation could be because there might be other 
markers which could mediate the function of the selected markers in the current study. For example, 
we did not examine the balance between pro-inflammatory and anti-inflammatory; thus, IL-1ra and  
IL-4 should be included in future studies because IL-4 is the inhibitor for IL-6, and IL-1ra (IL-1 
receptor antagonist) is the inhibitor for IL-1β [3,4]. Further study should also consider the mediators of 
the PNI biomarkers. 
5. Conclusions 
Poor sleep quality measured by the PSQI was the significant predictor for both depressive and 
physical symptoms, and the poor sleepers reported significantly more depressive and physical 
symptoms than the good sleepers. No statistical significance was found in the selected PNI biomarkers 
between the poor sleepers and good sleepers; however, higher serotonin levels and lower IL-10 levels 
were the significant predictors for depressive symptoms. Findings also showed circadian activity 
rhythms play a role in the individual’s well-being since delayed peak activity rhythms is the significant 
predictor for physical symptoms. 
The mission of NIH is to seek fundamental knowledge to enhance health, lengthen life, and reduce 
illness and disability, which emphasizes preventive care [44]. However, to date, the majority of studies 
regarding health outcomes are disease-oriented instead of using the preventive perspective by studying 
a healthy population. To use the general population could decrease the confounding impacts associated 
with the illness and provide better understanding the dynamics of sleep loss on molecular signaling 
pathways. A modest amount of sleep loss activates cellular markers of inflammatory responses, which 
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are associated with up-regulation of molecular pathways that affects message abundance of inflammatory 
signaling pathways [45]. 
It has been reported that the risk factors for sleep problems are associated with older age, less 
education, smoking, being underweight, morbidity, and people racially identified as Black [46]. In the 
current study, the participants were well-educated, healthy young adults, with an average normal BMI; 
however, they were sleep deprived and with depressive and physical symptoms.  Sleep deprivation 
affects performance in decreased reaction times, less vigilance, an increase in perceptual and cognitive 
distortions, and changes in affect [47,48]. More research is needed to further explore the risk factors 
for sleep disturbances and to guide interventions for this specific healthy population to improve their 
health status. However, college curriculum should include educational materials in the areas of sleep 
hygiene, associations between sleep disturbances and adverse health outcomes, and strategies to 
maintain synchronized circadian rhythms are needed for college women. 
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